J&J's Caplyta Repeats Its Bipolar Mania Win in a Second Phase 3
- J&J said its second pivotal Phase 3 of Caplyta (lumateperone) in acute bipolar mania met the primary and key secondary endpoints.
- The first study read out in September; together they are intended to support a US submission for mania.
- Both trials ran three weeks, so maintenance efficacy and long-term safety are not addressed.
💡 Points Based on public reports
Two positive pivotal trials is what the FDA wants, and the second effect size was smaller than the first, which is worth noting for a label negotiation. Caplyta is a key piece of the Intra-Cellular deal, so this expands the addressable psychiatric market inside a crowded atypical-antipsychotic class. Differentiation will rest on tolerability versus metabolic burden rather than raw efficacy.
📰 Source · Johnson & Johnson ↗ Johnson & Johnson announces CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal Phase 3 study